SCHEMBL19164875

SCHEMBL19164875

Cc1[nH]ccc1CCNC1=NC(CCN(CCc2cc[nH]c2C)C2=NC(C)N=C(N)N2)N=C(N)N1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19144961 0.85 — —
SCHEMBL19165612 0.84 — —
SCHEMBL19165054 0.84 — —
SCHEMBL14872476 0.82 HTR5A (0.31) —
SCHEMBL19165044 0.81 — —
SCHEMBL19144956 0.80 — —
SCHEMBL19144930 0.78 ADORA3 (0.33) —
SCHEMBL19165601 0.77 ESR1 (0.35) —
SCHEMBL19164895 0.76 — —
SCHEMBL19145183 0.75 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170209394-A1 Biguanide Compositions and Methods of Treating Metabolic Disorders ANJI PHARMACEUTICALS INC. 2017-07-27 — — US disclosed
Send feedback